Glaukos Corporation Reports Strong Q1 2026 Earnings with Revenue Growth and Strategic Initiatives
Glaukos Corporation reported strong Q1 2026 earnings, driven by the success of its iDose TR product and growth in its U.S. glaucoma franchise. The company raised its full-year 2026 net sales guidance to $620 million to $635 million, reflecting confidence in new product adoption and strategic initiatives. International growth is expected to moderate due to currency and competitive factors.
Tickers: $GKOS
Topics: Earnings Financial Performance Product Launch Revenue Growth Strategic Initiatives